Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies
- VernacularTitle:程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展
- Author:
Yanting SHIH
1
;
Hao LI
;
Jie ZHENG
;
Hua CAO
Author Information
- Keywords: Programmed cell death 1 receptor; Myositis; Neoplasms; Immune checkpoint inhibitors; Anti-transcription intermediary factor 1-γ antibody
- From: Chinese Journal of Dermatology 2022;55(7):633-636
- CountryChina
- Language:Chinese
- Abstract: After the specific binding of programmed death-1 (PD-1) to programmed death ligand 1 (PD-L1) , the PD-1/PD-L1 complex can exert a co-suppressive/co-stimulatory immunoregulatory effect, which can inhibit the activation and proliferation of T cells and their cytokine secretion, and play a key role in tumor immunity, autoimmunity and immune tolerance. This review summarizes structures and regulatory mechanisms of the PD-1/PD-L1 signaling pathway, aimming to facilitate the understanding of immune pathogenesis of idiopathic inflammatory myopathies complicated by malignant tumors, and to seek potential therapeutic targets and diagnostic strategies.
